Lenire Biosciences Completes License Agreement with University College London for VSN16R, A Novel Clinical Candidate Treatment for Fragile X Syndrome
Retrieved on:
Thursday, June 16, 2022
Multiple sclerosis, Myalgia, Spasticity, Patent, Therapy, Attention deficit hyperactivity disorder predominantly inattentive, Attention, Learning, 2009 Davis Cup, University College London, Anxiety, Residential treatment center, Technology, Cincinnati, Attention deficit, Company, Cincinnati Children's Hospital Medical Center, Human, Research, BK, Professor, Autism, UCL Business, Psychiatry, Intellectual disability, Patient, Biomedical Research, UCL, Attention deficit hyperactivity disorder, Disorder, SAN, FXS, Fragile X syndrome, GLOBE, Prevalence, Syndrome, Pharmaceutical industry
The development of this technology was supported by UCL Business (UCLB), the commercialization company of UCL.
Key Points:
- The development of this technology was supported by UCL Business (UCLB), the commercialization company of UCL.
- FXS is a rare, inherited condition that can cause issues including developmental delays, learning and behavioural difficulties, physical abnormalities, anxiety, attention or hyperactivity disorders and autism spectrum disorder.
- FXS is the most prevalent inherited form of intellectual disability and a leading cause of autism spectrum disorder.
- Lenire Biosciences is privately held, clinical stage biopharmaceutical company that is developing novel, patent protected therapeutics for the treatment of Fragile X Syndrome (FXS), a leading cause of intellectual disability world-wide that also presents with anxiety, attention deficit, hyperactivity, autism spectrum behaviors and other disabling symptoms.